论文部分内容阅读
目的:研究升清降浊方(SQJZF)对L-谷氨酸钠(MSG)肥胖大鼠糖脂代谢的影响。方法:复制MSG肥胖大鼠模型,随机分为模型对照组、阳性药罗格列酮组、阳性药非诺贝特组、SQJZF高剂量组(6 g生药·kg-1)、SQJZF中剂量组(3 g生药·kg-1)、SQJZF低剂量组(1.5 g生药·kg-1);另取正常组大鼠8只。连续给药50 d,期间进行糖耐量实验和蔗糖耐量实验。给药50 d后检测随机血糖、血清脂质和空腹胰岛素含量。结果:升清降浊方有一定的改善糖耐量和胰岛素耐量的作用,能够显著降低空腹血清胰岛素含量(P<0.05或P<0.01),降低随机血糖和血清TC、TG的含量。结论:升清降浊方对MSG肥胖大鼠的糖脂代谢紊乱起到良好的调节作用。
Objective: To investigate the effects of SQQZZ on glucose and lipid metabolism in obese rats with L-glutamate (MSG). Methods: MSG obese rats were duplicated and divided randomly into model control group, rosiglitazone positive group, fenofibrate positive group, SQJZF high dose group (6 g crude drug · kg -1), SQJZF middle dose group (3 g crude drug · kg-1), SQJZF low dose group (1.5 g crude drug · kg-1), and another 8 normal rats. Continuous dosing 50 d, during which glucose tolerance test and sucrose tolerance test. 50 d after administration of random glucose, serum lipid and fasting insulin levels. Results: Shengqing Jiangzhuo prescription can improve glucose tolerance and insulin tolerance. It can significantly reduce fasting serum insulin (P <0.05 or P <0.01), reduce random blood glucose and serum TC, TG content. Conclusion: Shengqingjiangzhuo decoction can play a good regulatory role in the disorder of glucose and lipid metabolism in MSG obese rats.